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Abstract
Replication of retroviral and host genomes requires ribonucleotide reductase to convert rNTPs to dNTPs, which are then
used as substrates for DNA synthesis. Inhibition of ribonucleotide reductase by hydroxyurea (HU) has been previously used
to treat cancers as well as HIV. However, the use of HU as an antiretroviral is limited by its associated toxicities such as
myelosuppression and hepatotoxicity. In this study, we examined the ribonucleotide reductase inhibitor, gemcitabine, both
in cell culture and in C57Bl/6 mice infected with LP-BM5 murine leukemia virus (LP-BM5 MuLV, a murine AIDS model).
Gemcitabine decreased infectivity of MuLV in cell culture with an EC50 in the low nanomolar range with no detectable
cytotoxicity. Similarly, gemcitabine significantly decreased disease progression in mice infected with LP-BM5. Specifically,
gemcitabine treatment decreased spleen size, plasma IgM, and provirus levels compared to LP-BM5 MuLV infected,
untreated mice. Gemcitabine efficacy was observed at doses as low as 1 mg/kg/day in the absence of toxicity. Higher doses
of gemcitabine (3 mg/kg/day and higher) were associated with toxicity as determined by a loss in body mass. In summary,
our findings demonstrate that gemcitabine has antiretroviral activity ex vivo and in vivo in the LP-BM5 MuLV model. These
observations together with a recent ex vivo study with HIV-1[1], suggest that gemcitabine has broad antiretroviral activity
and could be particularly useful in vivo when used in combination drug therapy.
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Introduction
Retroviruses are a significant source of morbidity and mortality
worldwide. For example, there are 33 million people infected with
human immunodeficiency virus type 1 (HIV-1) whereas the
retrovirus, xenotropic murine leukemia virus like-virus (XMRV),
has recently been proposed to be linked to prostate cancer and
chronic fatigue syndrome (CFS) [2,3]. Although there are a number
of drugs available for HIV-1 chemotherapy, the efficacy of these
treatments is limited by the emergence of drug resistance, cost of
treatment, and off-target effects. These limitations necessitate the
development of new drugs and novel drug targets for HIV as well as
other retroviruses. Similarly, if XMRV is shown to be the etiological
agent of either prostate cancer and/or CFS, the development of
new drugs could reduce morbidity and mortality.
Current anti-retroviral drugs target viral proteins that are
necessary for viral replication and production. Under suboptimal
therapy, the combination of both the high rates of replication and
mutation leads to the emergence of drug resistance. Although
drugs that target host proteins could delay or prevent the
emergence of drug resistance, there are significant side effects
associated with inhibiting host proteins. While cellular deoxynu-
cleoside triphosphates (dNTPs) are necessary for host cell function,
even small changes in dNTP pools appear to affect viral
replication without significant cellular toxicity [4].
Previous studies have shown that hydroxyurea, which inhibits
the cellular enzyme ribonucleotide reductase effectively decreases
replication of HIV-1 and was recently shown to also inhibit
hepatitis C virus replication as well [5,6,7]. Nonetheless, several
factors make hydroxyurea undesirable as an antiviral including 1)
pharmacokinetics of hydroxyurea vary from person to person
making its plasma levels unpredictable and 2) significant toxicities
(pancreatitis, hepatotoxicity) are associated with the use of
hydroxyurea when used to treat HIV-1 infection. The toxicity of
hydroxyurea is further emphasized in the murine AIDS (MAIDS)
model in which all animals treated with hydroxyurea died from
drug-related toxicities [8].
Alternatives to hydroxyurea that have a more desirable
pharmacokinetic profile and lower toxicity concerns may offer a
new and useful treatment for retroviral infections. In fact, other
ribonucleotide reductase inhibitors have been shown to be more
effective and less toxic in the MAIDS model [9]. However, no
follow up studies have been published regarding their potential for
clinical use.
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citabine represents a potential alternative to hydroxyurea as it has
been shown to have two mechanisms of action including inhibition
of ribonucleotide reductase [10,11]. Gemcitabine is clinically-
approved for cancer therapy and its anti-cancer mechanism is
attributed to its ability to inhibit ribonucleotide reductase thereby
limiting dNTP pools available for DNA synthesis in cancer cells.
Since retroviruses may be more sensitive to dNTP pool alterations
than cellular polymerases, we hypothesized that gemcitabine
would be an alternative to hydroxyurea that could be translated to
clinical use for the treatment of retroviral infections when used in
combination with current anti-retroviral therapies.
In a recent study, we identified two clinically-approved drugs,
decitabine and gemcitabine, that had potent anti-HIV activity in
cell culture. The potency by which gemcitabine inhibited
infectivity suggested that it may be useful for the treatment of
retroviral infections when used with decitabine or in combination
with current antiretroviral therapies.
In this study, we examined the ability of gemcitabine to inhibit
replication of another retrovirus, murine leukemia virus in cell
culture. Additionally, we examined the efficacy and toxicity of
gemcitabine in vivo using LP-BM5 murine leukemia virus (LP-
BM5 MuLV, a murine AIDS model). We chose this animal model
as it has been used extensively to screen potential anti-HIV drugs
and has been validated with a number of clinically approved anti-
HIV drugs such as AZT and PMPA (tenofovir) that have relatively
broad antiretroviral activity [12,13,14]. In this study, we show that
gemcitabine decreased infectivity of MuLV in cell culture with no
detectable cytotoxicity. Similarly, gemcitabine decreased disease
progression in the MAIDS model at non-toxic doses although
toxicities were detected at doses just three times that of the
effective dose. Our findings, along with previous observations ([1]),
indicate that gemcitabine has relatively broad antiretroviral
activity with minimal toxicity and could be useful for in vivo
antiretroviral combination therapy.
Results
Gemcitabine inhibits MuLV in cell culture
Before examining the antiviral activity of gemcitabine in vivo,w e
first examined the ability of gemcitabine to inhibit MuLV in cell
culture. To do this, a GFP-tagged MuLV was pseudotyped with
VSV-G and used to infect target cells that had been pretreated
with increasing concentrations of gemcitabine. Flow cytometry
was then used to determine the percentage of infected cells. As
shown in Fig. 1A, gemcitabine potently decreased MuLV
infectivity in a concentration-dependent manner with an EC50
in the low nM range. Additionally, there was no toxicity seen at
the concentrations of gemcitabine needed to inhibit viral
replication when the cells were exposed to gemcitabine for the
same time as was used to assess gemcitabine’s effect on infectivity
(Fig. 1B).
Gemcitabine inhibits progression of MAIDS as detected
by spleen weight and histopathology
The data from Fig. 1 indicate that gemcitabine inhibits
replication of MuLV in cell culture. To examine the ability of
gemcitabine to inhibit MuLV in an in vivo system, we treated mice
infected with LP-BM5 with increasing doses of gemcitabine
(Table 1). Progression of MAIDS was characterized by extensive
lymphoproliferation, splenomegaly, increased IgM levels, the
development of lymphoma, and increased susceptibility to
infection [15,16,17,18].
Proliferation of lymphoid cells in the spleen contributes to the
splenomegaly observed in mice infected with LP-BM5 and is an
indicator of disease progression and disease severity [18]. To
determine if gemcitabine decreases splenomegaly, spleens were
obtained and weighed at the time of sacrifice. As expected, the
ratio of spleen to body weight was significantly increased in
infected animals that did not receive treatment (Fig. 2). Mice
treated with 1 or 2 mg/kg/day had an average ratio of spleen to
body weight that was significantly lower than the infected,
untreated mice. In fact, there was no significant difference in the
spleen to body weight ratio between the treated mice and those
that were not infected (Fig. 2).
Since gemcitabine significantly decreased spleen size in mice
infected with LP-BM5, we next examined whether the decrease in
spleen size correlated with a decrease in the histopathological
changes characteristic of MAIDS. Table 2 demonstrates that there
were no significant findings in spleen from two of the four
uninfected mice. The spleens of the other two uninfected mice
were identified as either reactive or as having a score of 1 (see
Materials and Methods for scoring system). Of all other groups,
the infected, untreated mice had the most severe lesions as the
Figure 1. Gemcitabine inhibits MuLV replication in cell culture in the absence of toxicity. 1A. Infectivity of MuLV. MuLV containing GFP
were produced from 293T cells and used to infect U373-MAGI-CXCR4CEM cells that were treated with the indicated concentrations of gemcitabine.
The data represents the average 6 SD of three independent experiments. 1B. Toxicity of gemcitabine in U373-MAGI-CXCR4CEM cells treated with the
indicated concentrations of gemcitabine. The data represents the average 6 SD of three independent experiments.
doi:10.1371/journal.pone.0015840.g001
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or higher, indicating extensive changes in splenic architecture and
significant expansion of lymphoid cells. In general, there was a
decrease in splenic lesion score as the dose of administered
gemcitabine increased. For example, all spleens from mice
receiving the highest dose of gemcitabine were normal, while 5
of the 6 mice in the 3 mg/kg/day treatment group had spleens
with no significant findings and 4 of the 6 mice in the 2 mg/kg/
day treatment group were within normal limits. Finally, 1 of the 7
mice from the 1 mg/kg/day treatment group had a spleen with
normal histology while the other 6 spleens received a score of 1,
indicating mild lesions.
Treatment with gemcitabine decreases MAIDS-
associated lesions in the lymph nodes
Infection with LP-BM5 destroys the architecture of lymph
nodes and alters the composition [18]. When detected, the
lymph nodes from infected or uninfected mice were examined by
histopathology as described in the Materials and Methods
section. Lymph nodes were only detectable in one of the four
uninfected mice (Table 3). These lymph nodes were scored as a
1, indicating an enlargement of the lymph nodes with diffuse
sheets of medium to large lymphoid cells while maintaining
corticomedullary architecture. Consistent with the spleen data,
the size and lesions of the lymph nodes was greatest in mice that
were infected but not treated (Table 3). Additionally, lymph
n o d e sb e c a m em o r ed i f f i c u l tt od e t e c ta st h ed o s eo fg e m c i t a b i n e
increased, indicating that gemcitabine decreased the extent of
lymph node enlargement. Consistent with this, the pathology of
lymph nodes from mice treated with the higher doses of
gemcitabine had lower scores indicating less severe lesions. For
example, 6 of the 7 mice treated with 1 mg/kg/day of gemcita-
bine received a score of 1, whereas all of the lymph nodes from
mice treated with either 2 or 3 mg/kg/day received scores that
were consistent with a decrease in disease progression when
compared to the untreated but infected mice or mice treated
with 1 mg/kg/day of gemcitabine.
Effect of gemcitabine on plasma IgM levels
Soon after infection with LP-BM5, mice demonstrate a
significant increase in plasma IgM levels that peak approximately
8–9 weeks post-infection [16,18]. Subsequently, IgM levels
decrease, but remain elevated compared to uninfected animals.
To examine the effect of gemcitabine on IgM levels, plasma was
isolated from whole blood collected from mice at the time of
sacrifice. As expected, infected but untreated animals demonstrat-
ed a significant increase in IgM levels compared to the uninfected
animals (Fig. 3). In contrast, treatment with 1 or 2 mg/kg/day of
gemcitabine significantly decreased IgM levels compared to the
untreated animals. Surprisingly, IgM levels from mice treated with
2 mg/kg/day of gemcitabine were significantly lower than that
seen in the uninfected animals.
Gemcitabine decreases provirus levels
The data pathology indicated that gemcitabine decreases the
severity or progression of murine AIDS. However, to more
directly determine if gemcitabine inhibits replication of LP-BM5,
provirus levels were quantified from spleen obtained at the time of
sacrifice. Levels of the defective provirus were normalized to 18S
rRNA levels as previously described [19]. The data shown in Fig. 4
revealed high levels of provirus in mice that were infected, but
untreated. Mice treated with either 1 or 2 mg/kg/day of
gemcitabine had negligible provirus levels that were comparable
to the uninfected control mice, indicating reduced viral
replication.
Table 1. Treatment groups for ex vivo analysis of gemcitabine*.
Treatment Group Infection Status Treatment
Number in group
at start of study
Number of surviving
mice at end of study
1 Not infected Saline 4 4
2 Infected Saline 4 4
3 Infected 1 mg/kg/day gemcitabine 7 7
4 Infected 2 mg/kg/day gemcitabine 7 4
5 Infected 3 mg/kg/day gemcitabine 7 0
6 Infected 4 mg/kg/day gemcitabine 7 0
7 Not Infected 4 mg/kg/day gemcitabine 4 0
*Treatment Groups, number of animals at the start of the study and the number of animals surviving at the end of the study.
doi:10.1371/journal.pone.0015840.t001
Figure 2. Ratio of spleen weights to body from mice infected
with LP-BM5 MuLV. Each symbol (circles, squares, and triangles)
represents one mouse. The average 6 SD is shown. Treatment groups
labeled with the same letter (eg. the 1 and 2 mg/kg/day groups are
both labeled with ‘‘b’’) are not statistically different from one another
whereas treatment groups labeled with different letters (eg. ‘‘a’’ from
one group and ‘‘b’’ for another group) are statistically different from
one another as determined by One-Way ANOVA with Tukey-Kramer
post-test p,0.05. n=4 for the untreated groups, n=7 for the mice
treated with 1 mg/kg/day and n=3 for mice treated with 2 mg/kg/day.
doi:10.1371/journal.pone.0015840.g002
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body weight
Body weight is often used as an indicator of toxicity in
laboratory animals. In this study, animals losing 15% or more of
their body mass were euthanized and such loss of weight was
attributed to drug-related toxicity. All mice treated with 3 and
4 mg/kg/day of gemcitabine, regardless of infection status, lost
15% or more body mass and were euthanized before the end of
the study. Fig. 5 shows the change in body weight of all mice at the
time of euthanasia. The data demonstrates that mice treated with
2 mg/kg/day of gemcitabine or higher lost body weight while
untreated mice or mice treated with 1 mg/kg/day of gemcitabine
gained body weight throughout the study.
Discussion
In the absence of a cure or vaccine for HIV-1 infection, the
identification of novel drug targets and the development of new
drugs is the best approach to address the emergence of resistance
as well as the complications associated with current therapies.
Drugs that target cellular proteins are less likely to be susceptible to
the emergence of drug resistance compared to the current anti-
HIV therapies which target viral proteins. However, drugs that
target cellular proteins are likely to be associated with an increase
in toxicity which may limit their clinical use. For example,
hydroxyurea has been used alone and in combination with
nucleoside reverse transcriptase inhibitors (NRTIs) to decrease
viral loads in HIV-1 infected individuals. The side effects
associated with hydroxyurea has significantly curtailed its clinical
use. Less toxic alternatives to hydroxyurea would offer important
alternatives for the treatment of HIV-1 as well as other retroviral
infections.
A recent study demonstrated that two clinically approved drugs,
decitabine and gemcitabine have potent anti-HIV activity in cell
culture when used alone or in combination [1]. Importantly, based
on gemcitabine’s potency and lack of toxicity, the data suggest that
gemcitabine may be a clinically relevant alternative to hydroxy-
urea for the treatment of retroviral infections.
In this study, we examined the antiretroviral activity of
gemcitabine in vivo and ex vivo using the LP-BM5 MuLV model
(a murine AIDS model). Murine AIDS is caused by a combination
of three murine leukemia viruses including BM5-eco, BM5def, and
mink cell focus inducing virus (MCF) [20,21]. BM5def is a
retrovirus that is unable to replicate due to deletion of most of the
pol gene. However, its intact gag gene is thought to be responsible
for MAIDS pathogenesis. Although LP-BM5 is not a perfect
model for AIDS pathogenesis, it is well characterized, safe,
inexpensive, and has been validated with a number of clinically
approved anti-HIV-1 drugs and has been useful for identifying
drugs with broad antiretroviral activity (for review see [12].
Our studies found that gemcitabine decreased replication of
MuLV in cell culture as well as in vivo using the MAIDS model. In
Table 2. Histopathological analysis of spleen from gemcitabine-treated animals infected with LP-BM5.*









NSF 2 1 NSF NSF NSF
NSF 2 1 NSF NSF NSF
R 2 1 Ab NSF NSF
1 3 NSF NSF NSF NC
1 NSF NSF NC
1 D Ab NC
1 N CN CN C
*Sections of spleen were analyzed as described in Materials and Methods. NSF= no significant findings; R= reactive, Ab=Abnormal composition; D= depleted white
pulp. NC = tissue was not collected. Score of 3 = high pathology; score of 2 = intermediate pathology; score of 1 = low degree of pathology. Each box corresponds to
a different animal.
doi:10.1371/journal.pone.0015840.t002
Table 3. Histopathological analysis of lymph nodes from gemcitabine-treated animals infected with LP-BM5 MuLV*.









ND 3 NSF NSF NSF N/A
ND 3 NSF NSF NSF N/A
ND 3 1 ND NSF N/A
1 2 1 ND N/A N/A
1 ND N/A N/A
1 N/A ND N/A
2 N/A ND N/A
*Sections of lymph nodes were analyzed as described in Materials and Methods. NSF= no significant findings; N/A = not applicable because tissues were not collected.
ND = lymph nodes from these animals were not detected. Scores of 3 = high degree of pathology; score of 2 = intermediate degree of pathology; score of 1 = low
degree of pathology. Each box corresponds to a different animal.
doi:10.1371/journal.pone.0015840.t003
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splenomegaly, histopathology of spleen and lymph nodes and
levels of IgM and provirus indicated reduced viral replication. The
reduction of provirus by gemcitabine further supported the
gemcitabine-mediated reduction in viral replication. There are
at least two mechanisms that could account for the decrease in
disease progression. First, gemcitabine could decrease dNTP levels
enough to decrease proliferation of infected cells. Second,
gemcitabine could alter dNTP levels such that viral replication is
inhibited without inhibition of cellular proliferation. These
mechanisms are likely to be dose dependent with low gemcitabine
doses preferentially inhibiting viral replication and higher doses
inhibiting both viral replication and cell proliferation. In support
of this, 2 mg/kg/day of gemcitabine caused a significant reduction
in IgM levels compared to the uninfected animals. This is likely
due to gemcitabine-mediated decrease in B cell proliferation. In
contrast, IgM levels from mice treated with 1 mg/kg/day had
levels comparable to the uninfected animals which suggest there
was not a significant reduction in B cell numbers compared to the
uninfected mice. The cell culture data also supported this assertion
as the decrease in replication was not associated with a significant
loss of cell numbers (Fig. 1B). These data indicate that
gemcitabine’s antiviral activity is distinct from its activity used to
treat human cancers. Furthermore, doses of gemcitabine used
clinically in cancer treatment are significantly higher than those
used in our study. For example, gemcitabine’s anti-cancer activity
is achieved with a dosing regimen that includes 1000 mg/m
2 given
once every week for seven weeks, followed by one week without
drug and additional rounds of treatment as needed [22]. In our
study, an antiviral effect was seen in animals at doses as low as
1 mg/kg which correlates to 3 mg/m
2 when using the BSA
method to convert the mouse dose to the human equivalent dose
(mouse dose multiplied by mouse km of 3) [23]. Although the
metabolism of gemcitabine in mice is likely different compared to
humans, the significant difference in dosing further supports that
the antiviral activity seen here is not due to inhibition of cell
proliferation.
Toxicity of gemcitabine was significant at higher doses. In fact,
all mice treated with 3 and 4 mg/kg/day lost 15% or greater of
their body weight during the study and as a result were
prematurely euthanized. However, the 1 mg/kg/day dose of
gemcitabine decreased disease pathology with no detectable
toxicity. Specifically, all of these animals gained body weight
similar to the uninfected animals. Additionally, these animals did
not show any signs of hepatotoxicity as detected by histopatho-
logical analysis (data not shown). The 2 mg/kg/day dose was also
effective at decreasing disease progression. However, some of the
mice in this treatment group showed signs of toxicity in the loss of
body weight while others in this group appeared to tolerate
gemcitabine well. Like the animals treated with 1 mg/kg/day
gemcitabine, there was no hepatotoxicity observed in animals
treated with 2 mg/kg/day gemcitabine. The extent to which
gemcitabine effected the animals in the 2 mg/kg group was not
limited to toxicity as the efficacy of gemcitabine’s antiviral activity
also varied (see Figure 2). Although it is not clear why the mice
Figure 3. Serum IgM levels from mice infected with LP-BM5
MuLV. Each symbol (circles, squares and triangles) represent one
animal. Treatment groups labeled with different letters are not
statistically different from one another while treatment groups labeled
with different letters are statistically different as determined by One-
Way ANOVA with Tukey-Kramer post-test p,0.05. n=4 for both the
untreated groups, n=7 for animals treated with 1 mg/kg/day, and n=5
for animals treated with 2 mg/kg/day gemcitabine.
doi:10.1371/journal.pone.0015840.g003
Figure 4. Provirus levels in mice infected with LP-BM5 MuLV.
Genomic DNA was extracted from mouse spleen and quantitative real
time PCR was performed to detect the defective MAIDS provirus.
Provirus levels were normalized to the 18S rRNA gene. Each symbol
(squares, circles, and triangles) represents one animal. The Pfaffel
modification of the DDCt method was used to assess gene expression.
Statistical significance was assessed by One-Way ANOVA with Tukey-
Kramer post-test with p,0.05 designated as significant.
doi:10.1371/journal.pone.0015840.g004
Figure 5. Change in body weights of mice infected with LP-BM5
MuLV and treated with the indicated doses of gemcitabine.
Each symbol (triangles, squares, circles, diamonds, and hatch marks)
represent one mouse. The average 6 SD is shown for each treatment
group.
doi:10.1371/journal.pone.0015840.g005
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variation could be minimized by increasing the number of animals
in each treatment group.
Although gemcitabine has been used as cancer chemotherapy
for many years, it has likely been neglected as an antiviral due to
its poor oral bioavailability, which would necessitate drug delivery
by injection. However, a prodrug for gemcitabine has been
described recently, making gemcitabine a more attractive
candidate for use in treatment of retroviral infections, including
highly drug-resistant HIV-1 [24]. If its bioavailability is improved,
gemcitabine could serve as a novel anti-HIV drug for those
resistant to the current therapies.
In summary, the findings of our study indicate that gemcita-
bine has potent antiretroviral activity in vivo and ex vivo using the
LP-BM5 MuLV model. These findings, along with previous
ex vivo HIV-1 studies with gemicitabine an decitabine, suggest
that gemcitabine has broad antiretroviral activity and could




SC-1/MuLV LP-BM5 cells, chronically infected with LP-BM5,
were obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH from Dr.
Herbert Morse and Dr. Janet Hartley [25,26,27]. 293T cells were
obtained from American Tissue Type Culture (ATCC). C57Bl/6
mice were purchased from Jackson Laboratories. DMEM was
purchased from MediaGrow. Gemcitabine was obtained from
Carbosynth (Berkshire, U.K.). The IgM Elisa kit was from Assay
Designs (Ann Arbor, MI). The plasmids, pCR-DEF and pCR-18S
were a kind gift from Dr. Mauro Magnani (University of Urbino,
Urbino, Italy) and have previously been described [28]. U373-
MAGI-CXCR4CEM cells were obtained from Dr. Michael Emer-
man through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH [29,30]. The plasmid,
pIRES2-EGFP was obtained from Clontech (Mountain View,
CA). The plasmids pMIGR1, pJK3, pL-VSV-G, and CMV-Tat
were kind gifts from Vineet Kewal Ramani (NCI-Fredrick). The
plasmid pMIGR1 is an MLV vector containing an IRES-GFP
element [31]; pJK3 contains GagPol driven off HIV-1 LTR [32].
pL-VSV-G is also driven off the HIV-1 LTR [32]; and CMV-Tat
allows transcription off the HIV-1 LTR [32].
Cell culture
SC-1/MuLV LP-BM5 cells and 293T cells were maintained in
DMEM containing 10% fetal clone 3 (FC3) serum (Hyclone,
Logan, VT) and pen/strep at 37uCi n5 %C O 2. U373-MAGI-
CXCR4CEM cells expressing the CD4 receptor and the CXCR4
co-receptor were maintained at 37uCi n5 %C O 2 in selection
media composed of DMEM with 10% FC3, 1 mg/mL puromycin,
0.1 mg/mL hygromycin, and 0.2 mg/mL neomycin.
Transfection of 293 T cells. pMIGR1 (13.9 mg), pJK3
(6.9 mg), pL-VSV-G (5.54 mg) and CMV-Tat (1 mg) were
transfected into 293T cells using the calcium phosphate method.
Forty-eight hours after transfection, cell culture supernatant was
collected and frozen at 280uC.
Drug Treatment/Flow Cytometry. U373-MAGI-CXCR4CEM
cells (62,000) were plated in 12-well dishes 24 h prior to drug
treatment. Twenty-four hours later, gemcitabine was added to
the cultures at the concentrations indicated in the legend to Fig. 1.
Two hours post-drug treatment, 500 ml of virus was added to
each culture. Twenty-four hours later, the medium containing
gemcitabine (or DMSO) was removed replaced with new media.
Twenty-four hours after the media change, the U373-MAGI-
CXCR4CEM cells were collected and analyzed by flow cytometry
to determine the percentage of cells expressing GFP. Infectivity
was normalized for each individual experiment by setting
the infectivity of the untreated cells to 100 for each experiment
and then multiplying the data from the other individual
treatments by the number used to convert the no drug treated
cells to 100.
Cellular Proliferation. Cellular proliferation was examined
using the CellTiter-Glo kit from Promega according to the
manufacturer’s instructions. U373-MAGI-CXCR4 cells (4,500/
well) were plated in a 96-well dish 24 h prior to drug treatment.
Cells were treated (or not) with gemcitabine for 24 h before
proliferation was assessed by luciferase activity. DMSO was used
as a control for the untreated cells. Ethanol (20%) was used as a
positive control for cellular toxicity. The data were converted to
relative cell number by setting the no drug treated cells at 100 for
each experiment and then multiplying each other sample data by
the number used to convert the no drug treated cells to 100. This
conversion was normalized for differences in luciferase activity
among different experiments.
Mice. Female C57BL/6 mice aged 8–10 wk old were
purchased from Jackson Laboratories (Sacramento, California)
and were housed in standard rodent shoebox caging without a
filter top at 2261uC with a 12 h light/dark cycle, 6065%
humidity, and 12 air changes/h. Mice were fed lab chow and
water ad libitum. The experimental protocol was approved by
the Department of Veterans Affairs Medical Center (Minneapolis,
MN) IACUC committee (IACUC protocol number 0803A28341).
Infection of mice with LP-BM5 MuLV
LP-BM5 was produced from confluent SC-1 cells by filtering
the cell supernatant through a 0.25 mm syringe. The filtered viral
supernatant was maintained at 280uC until inoculation was
performed. C57BL/6 mice were inoculated with two intraperito-
neal injections of 0.25 mL of viral supernatant or DMEM spaced
three days apart.
Treatment of LP-BM5 MuLV infected mice with
gemcitabine
C57BL/6 mice were randomly divided into 7 groups including:
1) uninfected untreated; 2) uninfected treated with 4 mg/kg/day
gemcitabine; 3) infected, untreated; 4) infected treated with 1 mg/
kg/day; 5) infected with 2 mg/kg/day; 6) infected, treated with
3 mg/kg/day; and 7) infected, treated with 4 mg/kg/day. All
mice were treated daily with either gemcitabine or phosphate
buffered saline (PBS) for 8 wk beginning 1 wk post-infection.
Animals were weighed daily to achieve proper dosing and to detect
changes in body mass due to toxicity or infection. Animals did not
receive drug treatment 24 h prior to sacrifice.
Sacrifice of animals
Animals were euthanized either 8 wk post-drug treatment or
when animals lost 15% or greater body mass due to toxicity
associated with treatment. Animals were weighed and anesthetized
with 100 mg/kg ketamine plus 10 mg/kg xylazine prior to blood
collection from the submandibular vein. After euthanasia, spleens
were removed, weighed, and sectioned for histopathological
analysis as well as for the quantification of proviral levels. Lymph
nodes, when detected, were obtained and sectioned for histopath-
ological analysis as was liver. Necropsy was performed to assess
any gross abnormalities in any organs.
Antiretroviral Activity of Gemcitabine
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Histological examination and scoring of spleen was performed
by A.C.V.P. board certified veterinary pathologists from the
University of Minnesota Masonic Cancer Center Comparative
Pathology Shared Resource. The severity of lymphoproliferation
within the spleen was scored based on a previously published
scoring system [33,34] with slight modifications as follows:
1) Normal spleen (N) demonstrated normal architecture and a
ratio of while pulp to red pulp (W:R) of # ,1:1. 2) Spleens
designated as reactive (R) were defined as having reactive germinal
center expansion with a W:R ratio of ,2:1. Germinal centers in
these spleens were prominent and expanded. 3) Spleens designated
as a score of 1 were characterized by more extensive germinal
center expansion that those in the reactive group, with a W:R ratio
of ,3:1. Lymphoid nodules in these spleens were not coalescent
and had prominent mantle zones. 4) Spleens designated with a
score of 2 contained multifocal large lymphoid nodules that
coalesced and resulted in effacement of red pulp and mantle zones.
The W:R ratio in these spleens was ,4:1. 5) Spleens designated as
a score of 3 were characterized by extensive proliferation of
medium to large lymphoid cells that nearly completely effaced the
red pulp and mantle zones of the lymphoid nodules. The W:R
ratio in these spleens was .4:1. 6) Finally, spleens defined as D
were characterized by lymphoid depletion within white pulp.
Lymph node histopathology
A scoring system for lymph nodes in MAIDS mice has not been
previously reported. Scoring of lymph node lesions was similar to
that described for the spleen and was done using following grading
scheme: 1) Normal (N) was defined as lymph nodes demonstrating
normal architecture. 2) Reactive (R) was defined as lymph nodes in
which the corticomedullary architecture was maintained, but the
lymphoid follicles had enlarged germinal centers 3) A score of 1
was defined by moderately enlarged lymph nodes with diffuse
sheets of medium to large lymphoid cells while still maintaining
some follicular structures and corticomedullary architecture. 4) A
score of 2 was defined as diffusely enlarged lymph node where the
corticomedullary architecture was absent, but a rim of small
lymphocytes was present beneath the capsule. Finally, 5) lymph
nodes designated with a score of 3 were diffusely enlarged, and
contained medium to large lymphocytes that infiltrated the lymph
node capsule and extended into adjacent tissues.
Serum immunoglobulin M determination
After 8 wk of treatment, IgM levels were determined by ELISA
as per the manufacturers’ instructions (Assay Designs, Ann Arbor,
MI). Plasma was isolated from whole blood by centrifugation at
1,0006g for 10 minutes at room temperature and stored at 280uC
until the assay was performed. A standard curve was generated
using a standard IgM of known concentration and a correlation
coefficient (R
2)o f.0.98 was considered acceptable data for
analysis. All samples were run in triplicate and to confirm
reproducibility between assays, a subset of samples was run in
three independent experiments.
Determination of provirus levels from spleen
At 8 wk post-treatment, BM5d DNA content was assayed from
genomic DNA isolated from spleen. Total cellular DNA was
isolated using the Roche kit as per the manufacturers’ instructions.
BM5d DNA was quantified by real-time PCR assay as previously
described [19]. The amount of BM5d DNA in spleen was
calculated by interpolation of the experimentally determined
plasmid standard curve and was normalized to 18S rRNA. SYBR
green mastermix (Applied Biosystems) containing genomic DNA
(1 ml) and 25 pM of primers. The primers used to detect BM5def
were 59 CCTTTATCGACACTTCCCTTTT 39 and 59 TGGC-
AGAGGAGGAAGGTT39. The primers used to detects 18S
rRNA were: 59 GTAACCCGTTGAACCCCATT (forward) and
59CCATCCAATCGGTAGTAGGG (reverse). Conditions for
amplification of BM5Def and 18S rRNA included an initial heat
activation of the polymerase at 95uC for 13 min followed by 40
cycles of 95uC for 15 sec and 62uC for one min. Samples were
then heated to 72uC for 5 min, 95uC for 1 min prior to
performing a melt curve analysis from 55uCt o9 5 uC. Data was
used for analysis only when the standard curve for each primer set
yielded an R
2 of .0.99 with an efficiency of 90–110%, single
peaks were observed in the melt curves and template controls gave
no detectable amplification. Proviral levels normalized to 18S
rRNA levels by the Pfaffel method of quantification and were
determined in triplicate for each set of reactions and three
independent assays were performed with each sample.
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